CHRS
Coherus Oncology, Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies re-entered | Q3 2024(8Q snapshot) | 7Q | $1.43 | $1.49 | +4% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $1.37 | $1.49 | +9% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $1.37 | $1.49 | +9% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $1.37 | $1.49 | +9% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $1.37 | $1.49 | +9% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management | Q1 2025 | Q2 2025 | → $0.77 | -35% |
| Glenview Capital | Q2 2020 | Q3 2020 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Coherus Oncology, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 9, 2026 — the most recent Form 4 on file — not from today.
- Form 40001610717-26-000206Jun 9, 2026
- Form 40001610717-26-000205Jun 9, 2026
- Form 40001610717-26-000204Jun 9, 2026
- Form 40001610717-26-000203Jun 9, 2026
- Form 40001610717-26-000202Jun 9, 2026
- Form 40001610717-26-000201Jun 9, 2026
- Form 40001610717-26-000200Jun 9, 2026
- Form 40001104659-26-069622Jun 2, 2026
- Form 40001104659-26-069621Jun 2, 2026
- Form 40001610717-26-000027Jan 26, 2026
- Form 40001610717-26-000026Jan 26, 2026
- Form 40001610717-26-000017Jan 22, 2026
- Form 40001610717-26-000016Jan 22, 2026
- Form 40001610717-25-000229Jun 13, 2025
- Form 40001610717-25-000228Jun 13, 2025
Fundamentals
XBRL · Coherus Oncology, Inc.Annual figures sourced directly from Coherus Oncology, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Coherus Oncology, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 1, 2026
- 10-QQuarterly reportMay 11, 2026
- 8-KMaterial eventMay 11, 2026
- DEF 14AProxy statementApr 20, 2026
- 10-KAnnual reportMar 9, 2026
- 8-KMaterial eventMar 9, 2026
- 8-KMaterial eventFeb 17, 2026
- 8-KMaterial eventFeb 4, 2026
- 8-KFORM 8-KJan 23, 2026
- 8-KMaterial eventJan 13, 2026
- S-3Registration (shelf)Nov 13, 2025
- 8-KMaterial eventNov 13, 2025
- 10-QQuarterly reportNov 6, 2025
- 8-KMaterial eventNov 6, 2025
- 8-KMaterial eventSep 8, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q2 2026 | open | $1.57 | $1.49 | -5% |
| Millennium Management | Q1 2026 | open | $1.61 | $1.49 | -7% |
| Two Sigma Investments | Q4 2025 | open | $1.19 | $1.49 | +25% |
| Citadel Advisors | Q3 2025 | Q1 2026 | $1.02 | $1.61 | +58% |
| Renaissance Technologies | Q2 2025 | open | $0.79 | $1.49 | +89% |
| Point72 Asset Management | Q1 2025 | Q2 2025 | $1.18 | $0.77 | -35% |
| Citadel Advisors | Q3 2024 | Q1 2025 | $1.37 | $1.18 | -14% |
| Two Sigma Investments | Q3 2024 | Q2 2025 | $1.37 | $0.77 | -44% |
| AQR Capital Management | Q3 2024 | open | $1.37 | $1.49 | +9% |
| Millennium Management | Q3 2024 | Q4 2025 | $1.37 | $1.19 | -13% |
| Renaissance Technologies | Q3 2024 | Q1 2025 | $1.43 | $1.16 | -19% |
| Glenview Capital | Q2 2020 | Q3 2020 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.